Tech Company Financing Transactions
Dragonfly Therapeutics Funding Round
On 3/23/2020, Dragonfly Therapeutics announced funding from Fidelity Management & Research Company and private investors.
Transaction Overview
Company Name
Announced On
3/23/2020
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Fidelity Management & Research Company (Lead Investor)
Proceeds Purpose
A new round of investment will allow Dragonfly to further accelerate development of its novel innate immune system and Natural Killer cell-based immunotherapies into the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
35 Gatehouse Dr.
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Not Recorded
Overview
Dragonfly's therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses, and are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies -- such as T cell treatments.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Patrick Hwu
Chief Executive Officer
William Haney
Co-Founder
Tyler Jacks
Co-Founder
David Raulet
Vice President
Alan Korman
Browse more venture capital transactions:
Prev: 3/23/2020: Addepar venture capital transaction
Next: 3/23/2020: Oncoheroes Biosciences venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs